Infectious Disease Diagnostics Market Key Insights, Profiling Companies and Growth Strategies by 2027- Exclusive Report by MarketsandMarkets™

 Breaking News
  • No posts were found

Infectious Disease Diagnostics Market Key Insights, Profiling Companies and Growth Strategies by 2027- Exclusive Report by MarketsandMarkets™

March 03
21:25 2023
Infectious Disease Diagnostics Market Key Insights, Profiling Companies and Growth Strategies by 2027- Exclusive Report by MarketsandMarkets™
Browse 164 market data Tables and 51 Figures spread through 294 Pages and in-depth TOC on “Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) – Global Forecast to 2027
The increasing focus on patient safety and the need for rapid diagnosis are contributing to the growth of the infectious disease diagnostics market.

According to the new market research report “Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) – Global Forecast to 2027″, published by MarketsandMarkets™, the market is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR. This growth is attributed to the rising prevalence of infectious diseases, advancements in technology, and increasing demand for diagnostic tests.

Infectious diseases are caused by pathogens, such as bacteria, viruses, and fungi, which can spread from person to person or through contact with infected animals and food. Diagnosing infectious diseases is important as it helps to identify the cause of the disease, enabling doctors to provide appropriate treatment.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

The market is segmented based on technology, product, end-user, and region. Based on technology, the market is divided into polymerase chain reaction (PCR), nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), rapid test, and others. The PCR segment is expected to hold the largest market share during the forecast period due to its accuracy and sensitivity.

Based on products, the market is divided into instruments, reagents, and software and services. Instruments are further subdivided into PCR instruments, NAT instruments, ELISA instruments, and others. The reagents segment is expected to hold the largest market share during the forecast period due to the increasing demand for reagents for various diagnostic tests.

Based on end-user, the market is divided into hospitals, diagnostic centers, and clinical laboratories. The hospitals segment is expected to hold the largest market share during the forecast period due to the increasing number of hospitals and diagnostic centers across the globe.

Geographically, the market is segmented into North America, Europe, Asia-Pacific, and the rest of the world. North America is expected to hold the largest market share during the forecast period due to the presence of key players and the increasing prevalence of infectious diseases in the region.

Key Market Players

The major players operating in this infectious disease diagnostics market are  Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Siemens Healthineers AG (Germany), Danaher Corporation (US), Becton, Dickinson and Company (US), PerkinElmer, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics Holdings plc (US), Quidel Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech Plc. (Ireland), Chembio Diagnostic Systems (US), Seegene, Inc. (South Korea), Co-Diagnostics (US), ELITechGroup (France), Epitope Diagnostics (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International (US), Vela Diagnostics (Singapore) and Uniogen Oy (Finland).

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

This report categorizes the infectious disease diagnostics market into the following segments and subsegments:

By Product

  • Reagents, Kits, and Consumables
  • Instruments
  • Software & Services

By Type of Testing

  • Laboratory Testing
  • POC Testing

By Technology

  • Immunodiagnostics
  • Clinical Microbiology
  • PCR
  • INAAT
  • DNA Sequencing & NGS
  • DNA Microarray
  • Other technologies

By Disease Type

  • COVID-19
  • HIV
  • Hospital-acquired Infections
  • Hepatitis
  • Chlamydia Trachomatis
  • Neisseria Gonorrhea
  • HPV
  • Tuberculosis
  • Influenza
  • Syphilis
  • Mosquito-borne Diseases
  • Other Infectious Diseases

By End User

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Academic Research Institutes
  • Other End Users

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments

  • In November 2022, Roche Diagnostics Launched cobas 5800 system.
  • Thermo Fisher Scientific acquired Mesa Biotech (US) to expand the benefits of molecular diagnostics at the point of care.
  • Abbott Laboratories launched the ID NOW COVID-19 Test.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=116764589

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/infectious-disease-diagnostics-market-116764589.html

Categories